20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ARS Pharmaceuticals, Inc (SPRY) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 195 employees. Its market capitalization is roughly $336 million. In the fiscal year ended 2025-12-31, SPRY reported $84M in revenue and ($171M) in net income.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Interactive charts & full statements → Open the SPRY valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $117M | $84M | $89M | $0M | $1M | $6M | $18M | — | — |
| Gross Profit | $86M | $64M | $69M | $0M | ($16M) | $5M | $4M | ($2M) | ($1M) |
| Gross Margin % | 73.9% | 75.8% | 76.9% | 100.0% | -1200.9% | 96.1% | 21.1% | — | — |
| Operating Income (EBIT) | ($216M) | ($179M) | ($3M) | ($68M) | ($36M) | ($19M) | $0M | ($24M) | ($18M) |
| Operating Margin % | -185.0% | -212.9% | -3.5% | -225066.7% | -2698.8% | -353.3% | -2.6% | — | — |
| Net Income | ($215M) | ($171M) | $8M | ($54M) | ($35M) | ($20M) | ($1M) | ($24M) | ($18M) |
| Net Margin % | -184.2% | -203.3% | 9.0% | -181216.7% | -2635.4% | -367.6% | -6.0% | — | — |
| EBITDA | ($207M) | ($167M) | $8M | ($54M) | ($34M) | ($20M) | $0M | ($23M) | ($17M) |
| Earnings Per Share (EPS) | $-2.18 | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 | $-0.03 | $-0.72 | $-0.53 |
| Shares Outstanding (M) | 99M | 99M | 102M | 95M | 40M | 29M | 35M | 33M | 33M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $34M | $23M | $28M | $33M | $16M | $8M | $87M | $2M |
| Gross Profit | $21M | $16M | $25M | $24M | $11M | $4M | $83M | $2M |
| Gross Margin % | 61.8% | 72.3% | 88.6% | 74.8% | 68.3% | 49.2% | 95.5% | 94.6% |
| Operating Income (EBIT) | ($61M) | ($60M) | ($41M) | ($53M) | ($48M) | ($37M) | $47M | ($22M) |
| Operating Margin % | -182.6% | -265.2% | -147.6% | -163.7% | -302.9% | -466.3% | 54.5% | -1051.6% |
| Net Income | ($62M) | ($61M) | ($41M) | ($51M) | ($45M) | ($34M) | $50M | ($19M) |
| Net Margin % | -185.2% | -267.3% | -147.1% | -157.4% | -285.6% | -425.7% | 57.7% | -924.9% |
| EBITDA | ($59M) | ($58M) | ($41M) | ($49M) | ($45M) | ($34M) | $50M | ($19M) |
| Earnings Per Share (EPS) | $-0.63 | $-0.61 | $-0.42 | $-0.52 | $-0.46 | $-0.35 | $0.51 | $-0.20 |
| Shares Outstanding (M) | 99M | 99M | 99M | 99M | 98M | 98M | 98M | 97M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($196M) | ($171M) | $14M | ($59M) | ($40M) | ($18M) | $9M | ($19M) | ($17M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($197M) | ($171M) | $13M | ($59M) | ($40M) | ($18M) | $8M | ($19M) | ($17M) |
| FCF Margin % | -168.1% | -203.1% | 14.6% | -198136.7% | -3060.6% | -319.9% | 45.7% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($61M) | ($45M) | ($43M) | ($47M) | ($40M) | ($41M) | $42M | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($61M) | ($45M) | ($43M) | ($47M) | ($40M) | ($41M) | $42M | ($15M) |
| FCF Margin % | -181.0% | -198.2% | -154.8% | -145.4% | -252.2% | -512.1% | 48.2% | -706.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $249M | $328M | $351M | $233M | $281M | $61M | $26M | $16M | $28M |
| Cash & Cash Equivalents | $8M | $41M | $51M | $71M | $211M | $60M | $25M | $10M | $20M |
| Total Liabilities | $237M | $213M | $94M | $2M | $9M | $93M | $40M | $21M | $9M |
| Total Debt (Short + Long-Term) | $97M | $97M | $0M | $0M | $0M | $9M | $10M | $12M | $4M |
| Total Shareholders' Equity | $13M | $114M | $257M | $231M | $273M | ($31M) | ($14M) | ($6M) | $18M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SPRY viewer.
About TickerBase · Data methodology & sources · Privacy · Terms